Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206310 | 1.00 | DPP4 (0.46) | DPP4FAP | |
| SCHEMBL5206320 | 1.00 | DPP4 (0.46) | DPP4FAP | |
| SCHEMBL3787988 | 0.74 | DPP4 (0.57) | DPP4FAP | |
| SCHEMBL3393660 | 0.74 | DPP4 (0.57) | DPP4FAP | |
| SCHEMBL3398160 | 0.74 | DPP4 (0.57) | DPP4FAP | |
| SCHEMBL3786751 | 0.74 | DPP4 (0.57) | DPP4FAP | |
| SCHEMBL20329734 | 0.74 | DPP4 (0.57) | DPP4FAP | |
| SCHEMBL5203481 | 0.73 | HSD17B10 (0.50) | DPP4FAP | |
| Hydrochloric Acid SCHEMBL5201624 | 0.72 | DPP4 (0.51) | DPP4FAP | |
| Hydrochloric Acid SCHEMBL5201615 | 0.72 | DPP4 (0.51) | DPP4FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| EP-1746086-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1333025-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072892-A1 | Cyanopyrrolidine derivatives | CCR9, OPRD1, CBR1 | DPP4 2412/4885FAP 3334/4885 |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | DPP4, DPP9, DPP3 | DPP4 1/4885FAP 40/4885 |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | CBR3, CBR1, TERT | DPP4 3721/4885FAP 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.